Last verified · v1.0

Calculator · health

Diffuse Large B Cell Lymphoma (Dlbcl) Prognosis Calculator — International Prognostic Index (Ipi)

Estimate DLBCL prognosis with the IPI calculator. Input five clinical variables — age, stage, LDH, ECOG, and extranodal sites — to calculate an IPI risk score.

FreeInstantNo signupOpen source

Inputs

Patient Age

Ann Arbor Stage

Serum LDH Level

ECOG Performance Status

Number of Extranodal Sites Involved

Estimated 5-Year Overall Survival

—

Get a plain-English breakdown of your result with practical next steps.

Estimated 5-Year Overall Survival—

The formula

How the
result is
computed.

What Is the International Prognostic Index (IPI)?

The International Prognostic Index (IPI) is a clinically validated scoring system designed to stratify patients with Diffuse Large B-Cell Lymphoma (DLBCL) — the most common aggressive non-Hodgkin lymphoma, representing approximately 25–30% of all NHL diagnoses in the United States — into risk groups that predict overall survival and guide treatment intensity. First published in 1993 by the International Non-Hodgkin's Lymphoma Prognostic Factors Project in the New England Journal of Medicine, the IPI was derived from a retrospective analysis of 2,031 patients treated with combination chemotherapy across multiple institutions worldwide. That landmark study identified five independent clinical predictors of outcome that remain central to DLBCL management more than three decades later.

The IPI Formula Explained

The IPI assigns one point for each of five adverse prognostic factors present at diagnosis. Total scores range from 0 (best prognosis) to 5 (worst prognosis):

Age > 60 years (+1 point): Older patients have reduced physiologic reserve and tolerate dose-intensive chemotherapy less well, independently worsening clinical outcomes regardless of disease stage.
Ann Arbor Stage III or IV (+1 point): Advanced-stage disease indicates bilateral or disseminated lymph node involvement, or extralymphatic organ invasion, reflecting substantially higher tumor burden than localized Stage I–II disease.
Serum LDH above the upper limit of normal (+1 point): Elevated LDH directly measures tumor cell turnover and proliferative bulk, and serves as one of the single strongest adverse prognostic markers in DLBCL biology.
ECOG Performance Status ≥ 2 (+1 point): Patients with ECOG scores of 2 (ambulatory but unable to perform any work activity) through 4 (completely disabled) face greater treatment-related toxicity and inferior survival compared to fully functional patients.
More than 1 extranodal site involved (+1 point): Widespread extralymphatic disease — involving organs such as bone marrow, liver, lung, or central nervous system — signals systemic spread that confers independent prognostic significance beyond Ann Arbor staging.

IPI Risk Categories and Survival Estimates

The total IPI score maps directly to four established risk categories. The following survival estimates derive from the original 1993 NEJM cohort treated with CHOP-based regimens prior to the rituximab era:

Low risk (score 0–1): 5-year overall survival approximately 73%; complete response rate approximately 87%.
Low-intermediate risk (score 2): 5-year overall survival approximately 51%; complete response rate approximately 67%.
High-intermediate risk (score 3): 5-year overall survival approximately 43%; complete response rate approximately 55%.
High risk (score 4–5): 5-year overall survival approximately 26%; complete response rate approximately 44%.

Worked Clinical Example

A 67-year-old patient presents with Stage IV DLBCL, serum LDH at 1.8× the upper limit of normal, ECOG performance status of 2, and involvement of two extranodal sites (bone marrow and liver). IPI calculation: age > 60 (+1) + Stage IV (+1) + elevated LDH (+1) + ECOG ≥ 2 (+1) + extranodal sites > 1 (+1) = 5 points — High Risk. Without rituximab, expected 5-year overall survival is approximately 26%; modern R-CHOP-based therapy yields substantially improved outcomes for this population.

The Rituximab Era: Revised IPI and Updated Survival Data

The addition of rituximab to CHOP chemotherapy transformed DLBCL prognosis across all IPI risk groups. As reviewed in PMC research on dynamic prognostic indices for DLBCL, the Revised IPI (R-IPI) recategorizes the same five variables into three groups that better reflect rituximab-era outcomes: very good risk (0 points, 4-year progression-free survival approximately 94%), good risk (1–2 points, approximately 80%), and poor risk (3–5 points, approximately 53%). According to SEER Cancer Stat Facts for DLBCL, the five-year relative survival rate for DLBCL now exceeds 60% across all stages combined — a marked improvement attributable to rituximab, improved supportive care, and novel agents such as polatuzumab vedotin. Despite these advances, the original IPI remains the universal standard for risk stratification at diagnosis and clinical trial enrollment.

Limitations of the IPI and Evolving Prognostic Tools

The IPI was developed before molecular subtyping of DLBCL, before routine PET-CT staging, and prior to the rituximab era. High-throughput genomic analyses have identified clinically distinct subgroups — including double-expressor lymphoma and double-hit/triple-hit lymphomas harboring concurrent MYC and BCL2 or BCL6 rearrangements — whose adverse outcomes exceed what IPI alone predicts. Clinicians increasingly integrate IPI with molecular biomarkers and functional imaging to build a more comprehensive prognostic picture for individual patients.

Clinical Applications of the DLBCL Prognosis Calculator

Oncologists apply the IPI score at diagnosis to drive several critical treatment and management decisions:

Treatment intensity selection: High-IPI patients may receive dose-dense regimens such as DA-R-EPOCH, CNS prophylaxis with high-dose methotrexate, or consolidation with autologous stem cell transplantation in first complete remission.
Clinical trial stratification: Most pivotal DLBCL trials — including those evaluating polatuzumab vedotin (Pola-R-CHP) and CAR-T cell therapies in earlier lines — use IPI to ensure balanced randomization arms across risk groups.
Prognosis communication: Oncologists use IPI scores to frame realistic expectations during shared decision-making conversations with patients and families, supporting informed consent and goals-of-care planning.
Response contextualization: Interim PET-CT findings carry different clinical implications depending on whether a patient entered treatment as low-risk or high-risk by IPI, directly informing decisions about therapy continuation, modification, or intensification.

Reference

Frequently asked questions

What IPI score indicates a good prognosis for DLBCL?

An IPI score of 0 or 1 indicates low-risk DLBCL, associated with a 5-year overall survival of approximately 73% in pre-rituximab studies and up to 90% or higher with modern R-CHOP-based therapy. Patients in this category demonstrate the best expected outcomes and typically respond well to standard first-line chemoimmunotherapy without requiring treatment intensification, dose escalation strategies, or consolidative autologous stem cell transplantation at first remission.

How does the Revised IPI (R-IPI) differ from the original IPI for DLBCL?

The Revised IPI uses the same five clinical variables as the original IPI but redistributes patients into three risk groups — very good (0 points, 4-year PFS approximately 94%), good (1–2 points, approximately 80%), and poor (3–5 points, approximately 53%) — to better reflect outcomes with rituximab-based R-CHOP regimens. The original four-group model became less discriminating after rituximab improved survival across all IPI categories simultaneously, reducing separation between adjacent risk groups and prompting the revised three-group stratification to restore clinical utility in the modern treatment era.

What does an elevated LDH level mean for DLBCL prognosis?

Elevated serum lactate dehydrogenase (LDH), defined as any value exceeding the laboratory upper limit of normal, signals rapid tumor cell turnover and high proliferative activity within DLBCL tissue. It is one of the single strongest adverse prognostic markers in the disease, correlating with bulky tumor burden, aggressive histologic features, and potential resistance to standard therapy. Markedly elevated LDH — exceeding 3× the upper limit of normal — often prompts more intensive staging workup, including bone marrow biopsy and CNS evaluation, and may influence selection of consolidation strategies.

Can the IPI score be used to predict CNS relapse risk in DLBCL?

While the IPI was not originally designed to predict CNS relapse specifically, higher IPI scores correlate with elevated CNS relapse risk in DLBCL. The CNS-IPI — a dedicated prognostic tool that adds kidney and adrenal gland involvement to the five standard IPI variables — provides more precise CNS risk stratification, identifying a high-risk subgroup with approximately 10–12% CNS relapse rate at 2 years. High-IPI patients with involvement of CNS-associated extranodal sites frequently receive systemic CNS prophylaxis using high-dose methotrexate or intrathecal chemotherapy administered during standard treatment cycles.

How does ECOG performance status affect DLBCL treatment eligibility and IPI scoring?

ECOG performance status directly determines a patient's physiologic capacity to tolerate aggressive chemotherapy regimens. Patients with ECOG scores of 0 (fully active) or 1 (restricted in strenuous activity but ambulatory) generally qualify for standard full-dose R-CHOP administered every 21 days. Those with ECOG 2 (ambulatory but unable to perform any work activities) may receive dose-attenuated or modified regimens, while ECOG 3–4 patients often require palliative or best-supportive-care approaches. A score of 2 or higher contributes one IPI point, reflecting the significantly poorer prognosis associated with functional impairment at the time of DLBCL diagnosis.

What treatment options exist for patients with a high IPI score (4–5) in DLBCL?

High-IPI DLBCL patients (scores 4–5) typically receive standard R-CHOP or dose-dense DA-R-EPOCH as first-line therapy depending on institutional practice, patient fitness, and molecular features. The Pola-R-CHP regimen (polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone) demonstrated superior progression-free survival versus R-CHOP in the POLARIX phase III trial, particularly among higher-IPI patients. Consolidation with autologous stem cell transplantation is considered in eligible patients achieving complete remission, and CNS prophylaxis with high-dose methotrexate is frequently incorporated given the elevated CNS relapse risk in this population.